Close menu




September 9th, 2021 | 11:42 CEST

Nordex, Water Ways Technologies, MorphoSys: How investors invest in the future

  • Investments
Photo credits: pixabay.com

The future is traded on the stock exchange. But what does it look like? It is not easy to make concrete predictions. That is one of the reasons why there are both positive and negative surprises on the stock market. But as an investor, you can help the odds, for example, by focusing on megatrends. Demographics, health, and sustainability are trends that will still be in place in ten years. We present three possible investments.

time to read: 3 minutes | Author: Nico Popp
ISIN: NORDEX SE O.N. | DE000A0D6554 , Water Ways Technologies | CA9411881043 , MORPHOSYS AG O.N. | DE0006632003

Table of contents:


    Nordex: Where is the journey heading?

    Nordex has been a sustainable stock from the very beginning - ten years ago, Nordex was already one of the top sellers on the trading floor. Recently, the share came under a bit of pressure. The reason: profitability was not as high as the market had hoped. On the other hand, however, the order books are full. As a result, Nordex is a good example of short-term irritations that should not unsettle investors: The climate change is near, renewable energies will dominate or at least be enormously expanded in the future. For Nordex, this can only be good news.

    But what is the share price doing? It has been drifting sideways for weeks with a slight downward trend. If it slips below the EUR 15 mark, things could get uncomfortable for the stock once again. In any case, a downward slide could last until EUR 13. Conversely, new upward potential could arise above EUR 17. Fundamentally, things do not look bad for the wind turbine manufacturer, but the share price is not keeping up. That suggests that it is better to watch the stock from the sidelines.

    Water Ways Technologies makes agriculture smart

    One stock where an overly passive stance can quickly pay off is Water Ways Technologies. The Israel-based Company with a home exchange in Canada develops irrigation solutions for agribusinesses. Smart agriculture has a vital role, especially in times of scarce water and increasing demand for food that is ideally healthy and free of pesticides. Water scarcity is considered one of the greatest risks facing humanity. Political analysts have even predicted wars due to water shortages or polluted rivers. Rivers are not considered lifelines for nothing - if too much water is taken from upstream or the water is polluted, conflicts of great consequence can arise. Water Ways Technologies addresses the root cause - agriculture. According to studies, agriculture is responsible for 70% of the world's water withdrawals. Acting smarter here seems like an intelligent approach.

    Israel has always been innovative when it comes to growing crisp vegetables and sweet fruits on barren land. Consequently, Israel is also considered the motherland of agricultural technology. Water Ways Technologies continues this tradition, using sensors and apps to make the most efficient use of water. The current Company's forerunners were founded in Israel in 2003, and Water Ways Technologies has been successfully listed in Toronto since 2019. The Company has since known how to leverage investor capital successfully: In June 2019, they established a subsidiary in Canada and in February 2020, a subsidiary company in China. One year later, the most successful deal in the Company's history followed in Asia with an order worth CAD 4 million. 2021 was also successful for Water Ways, with the first half of the year bringing revenues of CAD 12.1 million and EBITDA of CAD 832,000. Today, the Company is in a better position than a year ago in almost all areas. In addition, Water Ways Technologies plans to actively communicate its success in Europe in the coming weeks and months. Water is a precious commodity - likely, there is also good money to be made from it on the stock market. With Water Ways, investors can bet on a dynamic company that has just entered the growth path.

    MorphoSys: No party mood despite approval

    Business is traditionally volatile for companies such as biotech group MorphoSys. The Company recently received European market approval for a drug to treat malignant diseases of the lymphatic system. But new drugs always have high start-up costs. At the end of the first half, MorphoSys posted a loss of EUR 101 million. The share is also very weak again after a few positive days. The shock of the half-year loss has not yet been digested on the stock market, making the share rather uninteresting.


    Even if cancer drugs are a great hope for many patients, the MorphoSys share is currently not. Nordex is also presently lacking in imagination. Water Ways Technologies, on the other hand, looks much better. It is a small company that has only just found its way onto the growth path and operates in an attractive sector.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Stefan Feulner on November 29th, 2022 | 13:32 CET

    Nvidia, Meta Materials, SFC Energy - Strong signs

    • Technology
    • Investments
    • nanotechnology

    After turbulent months on the technology stock markets with high markdowns, a bottoming out is taking place across the board. While many companies are reporting better-than-expected figures, investors are also buying oversold companies whose quarterly figures were below analysts' consensus. Due to the still high fluctuation range, high trading profits can be expected.

    Read